Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 18, 2022 - Issue 1
Submit an article Journal homepage
9,036
Views
20
CrossRef citations to date
0
Altmetric
Immunotherapy – Reviews

Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders – Advances and challenges

Tapas Kumar Goswamia Immunology Section, ICAR-Indian Veterinary Research Institute, Bareilly, IndiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-0518-2179View further author information
ORCID Icon,
Mithilesh Singha Immunology Section, ICAR-Indian Veterinary Research Institute, Bareilly, IndiaORCID Iconhttps://orcid.org/0000-0003-2316-9303View further author information
ORCID Icon,
Manish Dhawanb Department of Microbiology, Punjab Agricultural University, Ludhiana, India;c The Trafford Group of Colleges, Manchester, UKORCID Iconhttps://orcid.org/0000-0002-7783-7138View further author information
ORCID Icon,
Saikat Mitrad Department of Pharmacy, Faculty of Pharmacy, University of Dhaka, Dhaka, BangladeshView further author information
,
Talha Bin Emrane Department of Pharmacy, BGC Trust University Bangladesh, Chittagong, BangladeshORCID Iconhttps://orcid.org/0000-0003-3188-2272View further author information
ORCID Icon,
Ali A. Rabaanf Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia;g College of Medicine, Alfaisal University, Saudi Arabia;h Department of Public Health and Nutrition, The University of Haripur, Haripur, PakistanORCID Iconhttps://orcid.org/0000-0002-6774-9847View further author information
ORCID Icon,
Abbas Al Mutairi Research Center, Almoosa Specialist Hospital, Al-Ahsa, Saudi Arabia;j College of Nursing, Princess Norah Bint Abdulrahman University, Riyadh, Saudi Arabia;k School of Nursing, Wollongong University, Wollongong, NSW, AustraliaORCID Iconhttps://orcid.org/0000-0002-9471-2767View further author information
ORCID Icon,
Zainab Al Alawil Division of Allergy and Immunology, College of Medicine, King Faisal University, Al-Ahsa, Saudi ArabiaORCID Iconhttps://orcid.org/0000-0002-7004-7694View further author information
ORCID Icon,
Saad Alhumaidm Administration of Pharmaceutical Care, Al-Ahsa Health Cluster, Ministry of Health, Al-Ahsa, Saudi ArabiaORCID Iconhttps://orcid.org/0000-0003-4552-4513View further author information
ORCID Icon &
Kuldeep Dhaman Division of Pathology, ICAR-Indian Veterinary Research Institute, Bareilly, IndiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7469-4752View further author information
ORCID Icon show all
Article: 2035117 | Received 14 Jul 2021, Accepted 22 Jan 2022, Published online: 03 Mar 2022

References

  • Arellano B, Graber DJ, Sentman CL. Regulatory T cell-based therapies for autoimmunity. Discov Med. 2016;22:73–16.
  • Matzinger P. The danger model: a renewed sense of self. Science (80-). 2002;296:301–05. doi:10.1126/science.1071059.
  • Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, Parizot C, Taflin C, Heike T, Valeyre D, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009;30:899–911. doi:10.1016/j.immuni.2009.03.019.
  • Gliwiński M, Iwaszkiewicz-Grześ D, Trzonkowski P. Cell-based therapies with T regulatory cells. BioDrugs. 2017;31:335–47. doi:10.1007/s40259-017-0228-3.
  • Mikami N, Kawakami R, Sakaguchi S. New Treg cell-based therapies of autoimmune diseases: towards antigen-specific immune suppression. Curr Opin Immunol. 2020;67:36–41. doi:10.1016/j.coi.2020.07.004.
  • Palomares O, Yaman G, Azkur AK, Akkoc T, Akdis M, Akdis CA. Role of Treg in immune regulation of allergic diseases. Eur J Immunol. 2010;40:1232–40. doi:10.1002/eji.200940045.
  • Wang S, Zou X, Zhang Y, Wang X, Yang W, Li Y. The generation and regulation of tissue-resident Tregs and their role in autoimmune diseases. J Immunol Res. 2020;2020:1–13. doi:10.1155/2020/8815280.
  • Rocamora-Reverte L, Melzer FL, Würzner R, and Weinberger B. The complex role of regulatory T cells in immunity and aging. Front Immunol 11 . 2021;616949. doi:10.3389/fimmu.2020.616949
  • Sampani E, Stangou M, Daikidou DV, Nikolaidou V, Asouchidou D, Dimitriadis C, Lioulios G, Xochelli A, Fylaktou A, Papagianni A. Influence of end stage renal disease on CD28 expression and T-cell immunity. Nephrology. 2021;26:185–96. doi:10.1111/nep.13784.
  • Sampani E, Daikidou DV, Lioulios G, Xochelli A, Mitsoglou Z, Nikolaidou V, Dimitriadis C, Fylaktou A, Papagianni A, Stangou M. CD28null and regulatory T cells are substantially disrupted in patients with end-stage renal disease due to diabetes mellitus. Int J Mol Sci. 2021;22:1–13. doi:10.3390/ijms22062975.
  • Trzonkowski P, Bieniaszewska M, Juścińska J, Dobyszuk A, Krzystyniak A, Marek N, Myśliwska J, Hellmann A. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells. Clin Immunol. 2009;133:22–26. doi:10.1016/j.clim.2009.06.001.
  • Mukhatayev Z, Ostapchuk YO, Fang D, and Le Poole IC. Engineered antigen-specific regulatory T cells for autoimmune skin conditions. Autoimmun Rev 20 3 . 2021;102761. doi:10.1016/j.autrev.2021.102761
  • Singer A, Adoro S, Park JH. Lineage fate and intense debate: myths, models and mechanisms of CD4- versus CD8-lineage choice. Nat Rev Immunol. 2008;8:788–801. doi:10.1038/nri2416.
  • Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012;30:531–64. doi:10.1146/annurev.immunol.25.022106.141623.
  • Nazzal D, Gradolatto A, Truffault F, Bismuth J, and Berrih-Aknin S. Human thymus medullary epithelial cells promote regulatory T-cell generation by stimulating interleukin-2 production via ICOS ligand. Cell Death Dis 5 9 . 2014;e1420. doi:10.1038/cddis.2014.377
  • Sakaguchi S, Sakaguchi N, Asano M, Itoh M, and Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155 3 :1151–64. Accessed date 1 August 1995. http://www.ncbi.nlm.nih.gov/pubmed/7636184
  • Burchill MA, Yang J, Vogtenhuber C, Blazar BR, Farrar MA. IL-2 receptor β-Dependent STAT5 activation is required for the development of Foxp3 + regulatory T cells. J Immunol. 2007;178:280–90. doi:10.4049/jimmunol.178.1.280.
  • Shevach EM, Thornton AM. tTregs, pTregs, and iTregs: similarities and differences. Immunol Rev. 2014;259:88–102. doi:10.1111/imr.12160.
  • Adeegbe DO, Nishikawa H. Natural and induced T regulatory cells in cancer. Front Immunol. 2013;4:4. doi:10.3389/fimmu.2013.00004.
  • Tang Q, Adams JY, Tooley AJ, Bi M, Fife BT, Serra P, Santamaria P, Locksley RM, Krummel MF, Bluestone JA. Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol. 2006;7:83–92. doi:10.1038/ni1289.
  • Allos H, Al Dulaijan BS, Choi J, Azzi J. Regulatory T cells for more targeted immunosuppressive therapies. Clin Lab Med. 2019;39:1–13. doi:10.1016/j.cll.2018.11.001.
  • Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol. 2003;3:253–57. doi:10.1038/nri1032.
  • Lui PPW, Cho I, Ali N. Tissue regulatory T cells. Immunology. 2020;161:4–17. doi:10.1111/imm.13208.
  • Panduro M, Benoist C, Mathis D. Tissue Tregs. Annu Rev Immunol. 2016;34(1):609–33. doi:10.1146/annurev-immunol-032712-095948.
  • Weiss JM, Bilate AM, Gobert M, Ding Y, de Lafaille MAC, Parkhurst CN, Xiong H, Dolpady J, Frey AB, Ruocco MG, et al. Neuropilin 1 is expressed on thymus-derived natural regulatory T cells, but not mucosagenerated induced Foxp3+ T reg cells. J Exp Med. 2012;209:1723–42. doi:10.1084/jem.20120914.
  • Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara T, Momose Y, Cheng G, Yamasaki S, Saito T, Ohba Y, et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science (80-). 2011;331:337–41. doi:10.1126/science.1198469.
  • Scharschmidt TC, Vasquez KS, Truong HA, Gearty SV, Pauli ML, Nosbaum A, Gratz IK, Otto M, Moon JJ, Liese J, et al. A wave of regulatory T cells into neonatal skin mediates tolerance to commensal microbes. Immunity. 2015;43:1011–21. doi:10.1016/j.immuni.2015.10.016.
  • Ohue Y, Nishikawa H. Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target? Cancer Sci. 2019;110:2080–89. doi:10.1111/cas.14069.
  • Toker A, Engelbert D, Garg G, Polansky JK, Floess S, Miyao T, Baron U, Düber S, Geffers R, Giehr P, et al. Active demethylation of the Foxp3 locus leads to the generation of stable regulatory T cells within the thymus. J Immunol. 2013;190:3180–88. doi:10.4049/jimmunol.1203473.
  • Darrasse J, Mardon G, Salomon BL, Catala MKD, Klatzmann D. Ontogeny of CD4+CD25+ regulatory/suppressor T cells in human fetuses. Blood. 2005;105:4715–21. doi:10.1182/blood-2004-10-4051.
  • Liu W, Putnam AL, Xu-yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Barbara BF, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006;203:1701–11. doi:10.1084/jem.20060772.
  • Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res. 1999;59:3128–33.
  • Vignali DAA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8:523–32. doi:10.1038/nri2343.
  • Sojka DK, Huang YH, Fowell DJ. Mechanisms of regulatory T-cell suppression - A diverse arsenal for a moving target. Immunology. 2008;124:13–22. doi:10.1111/j.1365-2567.2008.02813.x.
  • Romano M, Fanelli G, Albany CJ, Giganti G, Lombardi G. Past, present, and future of regulatory T cell therapy in transplantation and autoimmunity. Front Immunol. 2019;10:10. doi:10.3389/fimmu.2019.00010.
  • Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol. 2010;11:7–13. doi:10.1038/ni.1818.
  • Feuerer M, Hill JA, Kretschmer K, Von Boehmer H, Mathis D, Benoist C. Genomic definition of multiple ex vivo regulatory T cell subphenotypes. Proc Natl Acad Sci U S A. 2010;107:5919–24. doi:10.1073/pnas.1002006107.
  • Omenetti S, Pizarro TT, Bancu I, Lauzurica-Valdemoros R, Borràs FE. The Treg/Th17 axis: a dynamic balance regulated by the gut microbiome. Front Immunol. 2015;6:6. doi:10.3389/fimmu.2015.00006.
  • Liu Y, Tran DQ, Lindsey JW, Rhoads JM. The association of gut microbiota and treg dysfunction in autoimmune diseases. Adv Exp Med Biol. 2021;1278:191–203.
  • Gotot J, Gottschalk C, Leopold S, Knolle PA, Yagita H, Kurts C, Ludwig-Portugall I. Regulatory T cells use programmed death 1 ligands to directly suppress autoreactive B cells in vivo. Proc Natl Acad Sci U S A. 2012;109:10468–73. doi:10.1073/pnas.1201131109.
  • Iikuni N, Lourenço EV, Hahn BH, La Cava A. Cutting edge: regulatory T cells directly suppress B cells in systemic lupus erythematosus. J Immunol. 2009;183:1518–22. doi:10.4049/jimmunol.0901163.
  • Richards H, Williams A, Jones E, Hindley J, Godkin A, Simon AK, Gallimore A. Novel role of regulatory T cells in limiting early neutrophil responses in skin. Immunology. 2010;131:583–92. doi:10.1111/j.1365-2567.2010.03333.x.
  • Lewkowicz N, Klink M, Mycko MP, Lewkowicz P. Neutrophil - CD4+CD25+ T regulatory cell interactions: a possible new mechanism of infectious tolerance. Immunobiology. 2013;218:455–64. doi:10.1016/j.imbio.2012.05.029.
  • Tiemessen MM, Jagger AL, Evans HG, Van Herwijnen MJC, John S, Taams LS. CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proc Natl Acad Sci U S A. 2007;104:19446–51. doi:10.1073/pnas.0706832104.
  • Romano M, Fanelli G, Tan N, Nova-Lamperti E, McGregor R, Lechler RI, Lombardi G, Scottà C. Expanded regulatory T cells induce alternatively activated monocytes with a reduced capacity to expand T helper-17 cells. Front Immunol. 2018;9. doi:10.3389/fimmu.2018.01625.
  • Kullberg MC, Hay V, Cheever AW, Mamura M, Sher A, Letterio JJ, Shevach EM, Piccirillo CA. TGF-β1 production by CD4+CD25+ regulatory T cells is not essential for suppression of intestinal inflammation. Eur J Immunol. 2005;35:2886–95. doi:10.1002/eji.200526106.
  • Maj T, Wang W, Crespo J, Zhang H, Wang W, Wei S, Zhao L, Vatan L, Shao I, Szeliga W, et al. Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nat Immunol. 2017;18:1332–41. doi:10.1038/ni.3868.
  • Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol. 2008;9:239–44. doi:10.1038/ni1572.
  • Ziegler SF. FOXP3: of mice and men. Annu Rev Immunol. 2006;24:209–26. doi:10.1146/annurev.immunol.24.021605.090547.
  • Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, Wilkinson JE, Galas D, Ziegler SF, Ramsdell F. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet. 2001;27:68–73. doi:10.1038/83784.
  • Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova J-L-R, Buist N, Levy-Lahad E, Mazzella M, Goulet O, Perroni L, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001;27:20–21. doi:10.1038/83713.
  • Shimizu J, Yamazaki S, Takahashi T, and Ishida YSS. Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol. 2002;3 2 135–142. doi:10.1038/ni759
  • Longhi MS, Ma Y, Mieli-Vergani G, Vergani D. Regulatory T cells in autoimmune hepatitis. J Hepatol. 2012;57:932–33. doi:10.1016/j.jhep.2012.05.022.
  • Aghabi YO, Yasin A, Kennedy JI, Davies SP, Butler AE, and Stamataki Z. Targeting enclysis in liver autoimmunity, transplantation, viral infection and cancer. Front Immunol. 2021;12 662134. doi:10.3389/fimmu.2021.662134
  • Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, DeFor T, Levine BL, June CH, Rubinstein P, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2011;117:1061–70. doi:10.1182/blood-2010-07-293795.
  • Dijke IE, Hoeppli RE, Ellis T, Pearcey J, Huang Q, McMurchy AN, Boer K, Peeters AMA, Aubert G, Larsen I, et al. Discarded human thymus is a novel source of stable and long-lived therapeutic regulatory T cells. Am J Transplant. 2016;16:58–71. doi:10.1111/ajt.13456.
  • Safinia N, Vaikunthanathan T, Fraser H, Thirkell S, Lowe K, Blackmore L, Whitehouse G, Martinez-Llordella M, Jassem W, Sanchez-Fueyo A, et al. Successful expansion of functional and stable regulatory T cells for immunotherapy in liver transplantation. Oncotarget. 2016;7:7563–77. doi:10.18632/oncotarget.6927.
  • Marek-Trzonkowska N, Myśliwiec M, Dobyszuk A, Grabowska M, Derkowska I, Juścińska J, Owczuk R, Szadkowska A, Witkowski P, Młynarski W, et al. Therapy of type 1 diabetes with CD4+CD25highCD127-regulatory T cells prolongs survival of pancreatic islets - Results of one year follow-up. Clin Immunol. 2014;153:23–30. doi:10.1016/j.clim.2014.03.016.
  • Fraser H, Safinia N, Grageda N, Thirkell S, Lowe K, Fry LJ, Scottá C, Hope A, Fisher C, Hilton R, et al. A rapamycin-based GMP-compatible process for the isolation and expansion of regulatory T cells for clinical trials. Mol Ther - Methods Clin Dev. 2018;8:198–209. doi:10.1016/j.omtm.2018.01.006.
  • Janssens I, and Cools N. Regulating the regulators: is introduction of an antigen-specific approach in regulatory T cells the next step to treat autoimmunity? Cell Immunol. 2020;358 104236. doi:10.1016/j.cellimm.2020.104236
  • Wu D, Wong MQ, Vent-Schmidt J, Boardman DA, Steiner TS, and Levings MK. A method for expansion and retroviral transduction of mouse regulatory T cells. J Immunol Methods. 2021;488 112931. doi:10.1016/j.jim.2020.112931
  • Roth-Walter F, Adcock IM, Benito-Villalvilla C, Bianchini R, Bjermer L, Boyman O, Caramori G, Cari L, Fan Chung K, Diamant Z, et al. Immune modulation via T regulatory cell enhancement: disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases—An EAACI position paper of the Task Force on Immunopharmacology (TIPCO). Allergy Eur J Allergy Clin Immunol. 2021;76:90–113. doi:10.1111/all.14478.
  • Eggenhuizen PJ, Ng BH, Ooi JD. Treg enhancing therapies to treat autoimmune diseases. Int J Mol Sci. 2020;21:1–18. doi:10.3390/ijms21197015.
  • Desreumaux P, Foussat A, Allez M, Beaugerie L, Hébuterne X, Bouhnik Y, Nachury M, Brun V, Bastian H, Belmonte N, et al. Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn’s disease. Gastroenterology. 2012:143. doi:10.1186/1471-230X-12-143
  • Goldberg R, Scotta C, Cooper D, Nissim-Eliraz E, Nir E, Tasker S, Irving PM, Sanderson J, Lavender P, Ibrahim F, et al. Correction of defective T-Regulatory cells from patients with crohn’s disease by ex vivo ligation of retinoic acid receptor-α. Gastroenterology. 2019;156:1775–87. doi:10.1053/j.gastro.2019.01.025.
  • Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, Herold KC, Lares A, Lee MR, Li K. Type 1 diabetes immunotherapy using polyclonal Tregs. Sci Transl Med. 2015 Nov 25;7:315ra189. doi:10.1126/scitranslmed.aad4134.
  • Dall’Era M, Pauli ML, Remedios K, Taravati K, Sandova PM, Putnam AL, Lares A, Haemel A, Tang Q, Hellerstein M, et al. Adoptive Treg cell therapy in a patient with systemic lupus erythematosus. Arthritis Rheumatol. 2019;71:431–40. doi:10.1002/art.40737.
  • Terry LV, Oo YH. The next frontier of regulatory T cells: promising immunotherapy for autoimmune diseases and organ transplantations. Front Immunol. 2020;11:11. doi:10.3389/fimmu.2020.00011.
  • Groux H, O’Garra A, Bigler M, Rouleau M, Antonenko S, De Vries JE, Roncarolo MG. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997;389:737–42. doi:10.1038/39614.
  • Mottet C, Uhlig HH, Powrie F. Cutting edge: cure of colitis by CD4 + CD25 + Regulatory T Cells. J Immunol. 2003;170:3939–43. doi:10.4049/jimmunol.170.8.3939.
  • Goswami TK, Joardar SN, Ram GC, Banerjee R, Singh DK. Association of mycobacterium paratuberculosis in Crohn’s disease and Johne’s disease: a possible zoonotic threat. Curr Sci. 2000;79:1076–81.
  • Maul J, Loddenkemper C, Mundt P, Berg E, Giese T, Stallmach A, Zeitz M, Duchmann R. Peripheral and intestinal regulatory CD4+CD25high T cells in inflammatory bowel disease. Gastroenterology. 2005;128:1868–78. doi:10.1053/j.gastro.2005.03.043.
  • Foussat A, Cottrez F, Brun V, Fournier N, Breittmayer J-P, Groux H. A comparative study between T regulatory Type 1 and CD4 + CD25 + T cells in the control of inflammation. J Immunol. 2003;171:5018–26. doi:10.4049/jimmunol.171.10.5018.
  • Canavan JB, Scottà C, Vossenkämper A, Goldberg R, Elder MJ, Shoval I, Marks E, Stolarczyk E, Lo JW, Powell N, et al. Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn’s disease. Gut. 2016;65:584–94. doi:10.1136/gutjnl-2014-306919.
  • Brimnes J, Allez M, Dotan I, Shao L, Nakazawa A, Mayer L. Defects in CD8 + regulatory T cells in the lamina propria of patients with inflammatory bowel disease. J Immunol. 2005;174:5814–22. doi:10.4049/jimmunol.174.9.5814.
  • Marwaha AK, Crome SQ, Panagiotopoulos C, Berg KB, Qin H, Ouyang Q, Xu L, Priatel JJ, Levings MK, Tan R. Cutting edge: increased IL-17–secreting T cells in children with new-onset type 1 diabetes. J Immunol. 2010;185:3814–18. doi:10.4049/jimmunol.1001860.
  • Baeten P, Van Zeebroeck L, Kleinewietfeld M, Hellings N, Broux B. Improving the efficacy of regulatory T cell therapy. Clin Rev Allergy Immunol. 2021. doi:10.1007/s12016-021-08866-1.
  • Sugiyama H, Matsue H, Nagasaka A, Nakamura Y, Tsukamoto K, Shibagaki N, Kawamura T, Kitamura R, Ando N, Shimada S. CD4+CD25high regulatory T cells are markedly decreased in blood of patients with pemphigus vulgaris. Dermatology. 2007;214:210–20. doi:10.1159/000099585.
  • Yokoyama T, Matsuda S, Takae Y, Wada N, Nishikawa T, Amagai M, Koyasu S. Antigen-independent development of Foxp31 regulatory T cells suppressing autoantibody production in experimental pemphigus vulgaris. Int Immunol. 2011;23:365–73. doi:10.1093/intimm/dxr020.
  • Schmidt T, Willenborg S, Hünig T, Deeg CA, Sonderstrup G, Hertl M, Eming R. Induction of T regulatory cells by the superagonistic anti-CD28 antibody D665 leads to decreased pathogenic IgG autoantibodies against desmoglein 3 in a HLA-transgenic mouse model of pemphigus vulgaris. Exp Dermatol. 2016;25:293–98. doi:10.1111/exd.12919.
  • Izumi K, Bieber K, Ludwig RJ. Current clinical trials in pemphigus and pemphigoid. Front Immunol. 2019;10:10.
  • Buitrago-Molina LE, Pietrek J, Noyan F, Schlue J, Manns MP, Wedemeyer H, Hardtke-Wolenski M, and Jaeckel E. Treg-specific IL-2 therapy can reestablish intrahepatic immune regulation in autoimmune hepatitis. J Autoimmun. 2021;117 102591. doi:10.1016/j.jaut.2020.102591
  • Longhi MS, Mieli-Vergani G, and Vergani D. Regulatory T cells in autoimmune hepatitis: un updated overview. J Autoimmun. 2021;119 102619. doi:10.1016/j.jaut.2021.102619
  • Sebode M, Hartl J, Vergani D, Lohse AW. Autoimmune hepatitis: from current knowledge and clinical practice to future research agenda. Liver Int. 2018;38:15–22. doi:10.1111/liv.13458.
  • Longhi MS, Ma Y, Bogdanos DP, Cheeseman P, Mieli-Vergani G, Vergani D. Impairment of CD4+CD25+ regulatory T-cells in autoimmune liver disease. J Hepatol. 2004;41:31–37. doi:10.1016/j.jhep.2004.03.008.
  • Peiseler M, Sebode M, Franke B, Wortmann F, Schwinge D, Quaas A, Baron U, Olek S, Wiegard C, Lohse AW, et al. FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency. J Hepatol. 2012;57:125–32. doi:10.1016/j.jhep.2012.02.029.
  • Jeffery HC, Jeffery LE, Lutz P, Corrigan M, Webb GJ, Hirschfield GM, Adams DH, Oo YH. Low-dose interleukin-2 promotes STAT-5 phosphorylation, Treg survival and CTLA-4-dependent function in autoimmune liver diseases. Clin Exp Immunol. 2017;188:394–411. doi:10.1111/cei.12940.
  • Lim TY, Martinez-Llordella M, Kodela E, Gray E, Heneghan MA, Sanchez-Fueyo A. Low-dose interleukin-2 for refractory autoimmune hepatitis. Hepatology. 2018;68:1649–52. doi:10.1002/hep.30059.
  • Taubert R, Hardtke-Wolenski M, Noyan F, Wilms A, Baumann AK, Schlue J, Olek S, Falk CS, Manns MP, Jaeckel E. Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies. J Hepatol. 2014;61:1106–14. doi:10.1016/j.jhep.2014.05.034.
  • Esensten JH, Muller YD, Bluestone JA, Tang Q. Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: the next frontier. J Allergy Clin Immunol. 2018;142:1710–18. doi:10.1016/j.jaci.2018.10.015.
  • Tsokos GC, Lo MS, Reis PC, Sullivan KE. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2016;12:716–30. doi:10.1038/nrrheum.2016.186.
  • Humrich JY, Morbach H, Undeutsch R, Enghard P, Rosenberger S, Weigert O, Kloke L, Heimann J, Gaber T, Brandenburg S, et al. Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. Proc Natl Acad Sci U S A. 2010;107:204–09. doi:10.1073/pnas.0903158107.
  • Ohl K, Tenbrock K. Regulatory T cells in systemic lupus erythematosus. Eur J Immunol. 2015;45(2):344–55. doi:10.1002/eji.201344280.
  • Schmidt A, Rieger CC, Venigalla RK, Éliás S, Max R, Lorenz HM, Gröne HJ, Krammer PH, Kuhn A. Analysis of FOXP3+ regulatory T cell subpopulations in peripheral blood and tissue of patients with systemic lupus erythematosus. Immunol Res. 2017;65:551–63. doi:10.1007/s12026-017-8904-4.
  • Lee HY, Hong YK, Yun HJ, Kim YM, Kim JR, Yoo WH. Altered frequency and migration capacity of CD4+ CD25+ regulatory T cells in systemic lupus erythematosus. Rheumatology. 2008;47:789–94. doi:10.1093/rheumatology/ken108.
  • He J, Zhang X, Wei Y, Sun X, Chen Y, Deng J, Jin Y, Gan Y, Hu X, Jia R, et al. Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus. Nat Med. 2016;22:991–93. doi:10.1038/nm.4148.
  • Mizui M, Tsokos GC. Targeting regulatory T cells to treat patients with systemic lupus erythematosus. Front Immunol. 2018;9:786. doi:10.3389/fimmu.2018.00786.
  • Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–38. doi:10.1016/S0140-6736(16)30173-8.
  • Cao D, van Vollenhoven R, Klareskog L, Trollmo C, Malmström V. CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res Ther. 2004;6:6. doi:10.1186/ar1025.
  • Han GM, O’Neil-Andersen NJ, Zurier RB, Lawrence DA. CD4+CD25high T cell numbers are enriched in the peripheral blood of patients with rheumatoid arthritis. Cell Immunol. 2008;253(1–2):92–101. doi:10.1016/j.cellimm.2008.05.007.
  • Liu MF, Wang CR, Fung LL, Lin LH, Tsai CN. The presence of cytokine-suppressive CD4+CD25+ T cells in the peripheral blood and synovial fluid of patients with rheumatoid arthritis. Scand J Immunol. 2005;62:312–17. doi:10.1111/j.1365-3083.2005.01656.x.
  • Lawson CA, Brown AK, Bejarano V, Douglas SH, Burgoyne CH, Greenstein AS, Boylston AW, Emery P, Ponchel F, Isaacs JD. Early rheumatoid arthritis is associated with a deficit in the CD4+CD25high regulatory T cell population in peripheral blood. Rheumatology. 2006;45:1210–17. doi:10.1093/rheumatology/kel089.
  • Flores-Borja F, Jury EC, Mauri C, Ehrenstein MR. Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2008;105:19396–401. doi:10.1073/pnas.0806855105.
  • Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-α therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-β. J Exp Med. 2007;204:33–39. doi:10.1084/jem.20061531.
  • Miyara M, Gorochov G, Ehrenstein M, Musset L, Sakaguchi S, Amoura Z. Human FoxP3 + regulatory T cells in systemic autoimmune diseases. Autoimmun Rev. 2011;10:744–55. doi:10.1016/j.autrev.2011.05.004.
  • Morita T, Shima Y, Wing JB, Sakaguchi S, Ogata A, and Kumanogoh A. The proportion of regulatory T cells in patients with rheumatoid arthritis: a meta-Analysis. PLoS One. 2016;11 9 e0162306 doi:10.1371/journal.pone.0162306. .
  • Kelchtermans H, De Klerck B, Mitera T, Van Balen M, Bullens D, Billiau A, Leclercq G, Matthys P. Defective CD4+CD25+ regulatory T cell functioning in collagen-induced arthritis: an important factor in pathogenesis, counter-regulated by endogenous IFN-gamma. Arthritis Res Ther. 2005;7:402–15. doi:10.1186/ar1500.
  • Morgan ME, Flierman R, Van Duivenvoorde LM, Witteveen HJ, Van Ewijk W, Van Laar JM, De Vries RRP, Toes REM. Effective treatment of collagen-induced arthritis by adoptive transfer of CD25+ regulatory T cells. Arthritis Rheum. 2005;52:2212–21. doi:10.1002/art.21195.
  • Zaiss MM, Axmann R, Zwerina J, Polzer K, Gückel E, Skapenko A, Schulze-Koops H, Horwood N, Cope A, Schett G. Treg cells suppress osteoclast formation: a new link between the immune system and bone. Arthritis Rheum. 2007;56:4104–12. doi:10.1002/art.23138.
  • van Amelsfort JM, van Roon JA, Noordegraaf M, Jacobs KM, Bijlsma JW, Lafeber FP, Taams LS. Proinflammatory mediator-induced reversal of CD4+,CD25+ regulatory T cell-mediated suppression in rheumatoid arthritis. Arthritis Rheum. 2007;56:732–42. doi:10.1002/art.22414.
  • LeRoy EC, Medsger TJ. Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001;28:1573–76.
  • Frantz C, Auffray C, Avouac J, Allanore Y. Regulatory T cells in systemic sclerosis. Front Immunol. 2018;9. doi:10.3389/fimmu.2018.02356.
  • Antiga E, Quaglino P, Bellandi S, Volpi W, Del Bianco E, Comessatti A, Osella-Abate S, De Simone C, Marzano A, Bernengo MG, et al. Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea. Br J Dermatol. 2010;162:1056–63. doi:10.1111/j.1365-2133.2010.09633.x.
  • Kataoka H, Yasuda S, Fukaya S, Oku K, Horita T, Atsumi T, Koike T. Decreased expression of Runx1 and lowered proportion of Foxp3+ CD25+ CD4+ regulatory T cells in systemic sclerosis. Mod Rheumatol. 2015;25:90–95. doi:10.3109/14397595.2014.899736.
  • Klein S, Kretz CC, Ruland V, Stumpf C, Haust M, Hartschuh W, Hartmann M, Enk A, Suri-Payer E, Oberle N, et al. Reduction of regulatory T cells in skin lesions but not in peripheral blood of patients with systemic scleroderma. Ann Rheum Dis. 2011;70:1475–81. doi:10.1136/ard.2009.116525.
  • Tsukamoto H, Nagafuji K, Horiuchi T, Mitoma H, Niiro H, Arinobu Y, Inoue Y, To K, Miyamoto T, Iwasaki H, et al. Analysis of immune reconstitution after autologous CD34 + stem/progenitor cell transplantation for systemic sclerosis: predominant reconstitution of Th1 CD4 + t cells. Rheumatology. 2011;50:944–52. doi:10.1093/rheumatology/keq414.
  • Vonk MC, Marjanovic Z, Van Den Hoogen FHJ, Zohar S, Schattenberg AVMB, Fibbe WE, Larghero J, Gluckman E, Van Laar JM, Farge D, et al. Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann Rheum Dis. 2008;67:98–104. doi:10.1136/ard.2007.071464.
  • Verstappen GM, Kroese FGM, Bootsma H. T cells in primary Sjögren’s syndrome: targets for early intervention. Rheumatol (United Kingdom). 2021;60:3088–98.
  • Liu MF, Lin LH, Weng CT, Weng M. Decreased CD4+CD25+bright T cells in peripheral blood of patients with primary Sjogren’s syndrome. Lupus. 2008;17:34–39. doi:10.1177/0961203307085248.
  • Christodoulou MI, Kapsogeorgou EK, Moutsopoulos NM, Moutsopoulos HM. Foxp3+ T-regulatory cells in Sjögren’s syndrome: correlation with the grade of the autoimmune lesion and certain adverse prognostic factors. Am J Pathol. 2008;173:1389–96. doi:10.2353/ajpath.2008.080246.
  • Nussbaum L, Chen YL, Ogg GS. Role of regulatory T cells in psoriasis pathogenesis and treatment. Br J Dermatol. 2021;184:14–24. doi:10.1111/bjd.19380.
  • Dong F, Li XH, Zhang KM, Yin GH. Functional characterization of CD4+ CD25+ regulatory T cells differentiated in vitro from bone marrow-derived hematopoietic cells of psoriatic patients. J Clin Dermatology. 2008;37:207–09.
  • Zhang L, Yang XQ, Cheng J, Hui RS, Gao TW. Increased Th17 cells are accompanied by FoxP3+ Treg cell accumulation and correlated with psoriasis disease severity. Clin Immunol. 2010;135:108–17. doi:10.1016/j.clim.2009.11.008.
  • Sugiyama H, Gyulai R, Toichi E, Garaczi E, Shimada S, Stevens SR, McCormick TS, Cooper KD. Dysfunctional blood and target tissue CD4 + CD25 high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol. 2005;174:164–73. doi:10.4049/jimmunol.174.1.164.
  • Yun WJ, Lee DW, Chang SE, Yoon GS, Huh JR, Won CH, Lee MW, Kim SE, Kim BJ, Moon KC, et al. Role of CD4+CD25high+FOXP3+ regulatory T cells in psoriasis. Ann Dermatol. 2010;22:397–403. doi:10.5021/ad.2010.22.4.397.
  • Huang Z, Li W, Su W. Tregs in autoimmune uveitis. Adv Exp Med Biol. 2021;1278:205–27. doi:10.1007/978-981-15-6407-9_11.
  • Wu Y, Luo J, Garden OA, Christensen CB, Lildal T, Pedersen M, Magnusson M, Borghammer P, Ovesen T. Immunoregulatory cells in myasthenia gravis. Front Neurol. 2020;11:11. doi:10.3389/fneur.2020.00011.
  • Herrnstadt GR, Steinmetz OM. The role of Treg subtypes in glomerulonephritis. Cell Tissue Res. 2020;385(2):293–304. doi:10.1007/s00441-020-03359-7.
  • Neumann K, Tiegs G. Immune regulation in renal inflammation. Cell Tissue Res. 2021;385(2):305–22. doi:10.1007/s00441-020-03351-1.
  • Riley JL, June CH, Blazar BR. Human T regulatory cells as therapeutic agents: take a billion or so of these and call me in the morning. Immunity. 2010;30:656–65. doi:10.1016/j.immuni.2009.04.006.
  • Golab K, Leveson-Gower D, Wang XJ, Grzanka J, Marek-Trzonkowska N, Krzystyniak A, Millis JM, Trzonkowski P, Witkowski P. Challenges in cryopreservation of regulatory T cells (Tregs) for clinical therapeutic applications. Int Immunopharmacol. 2013;16:371–75. doi:10.1016/j.intimp.2013.02.001.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.